Biocomposites Limited - News
../News
News
 
Current News
geneX®ds. Extending the reach of injectable bone grafts. Now available in 5cc
Posted March 2011
Due to the success of the geneX ds system, and in response to requests for larger volume packs, Biocomposites is pleased to announce the availability of geneX ds 5cc.
New study using geneX for scaphoid non-unions shows promising results
Posted December 2010
A recent case series using geneX® in a minimally invasive technique shows promising results for the treatment of clinically challenging scaphoid non unions.
Biocomposites supports Haiti humanitarian effort
Posted January 2010
Biocomposites, the pioneers in ceramic materials for bone repair, has supported the humanitarian effort in Haiti by providing £10,000 worth of Stimulan® a synthetic bone graft material, to a leading US Orthopaedic surgeon from California, who is travelling with a team of medics, to the devastated region.
Biocomposites launches geneX®ds. Extending the reach of injectable bone grafts
Posted January 2010
Biocomposites, the pioneers in synthetic bone graft materials have launched geneX ds, a dual syringe mixing and minimally invasive delivery system containing geneX, the unique resorbable bone graft material with a negative surface charge.
geneX® Used in Pioneering Stem Cell Research
Posted September 2009
Professor James B. Richardson of the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK has been carrying out pioneering work combining geneX with selected and culture expanded Mesenchymal stem cells to treat fracture non-unions.

Biosteon® composite interference screws reduce tunnel widening after cruciate ligament reconstruction
Posted June 2009
A recent independent 200 patient study has concluded that Biosteon interference screws significantly improve implant / bone integration and thereby reduce tunnel widening and risk of graft slippage post-operatively in cruciate ligament surgery.

Allogran-N Shows Equivalence To Allograft In Revision Hip Surgery In 13 Year Follow Up Study
Posted June 2009
A recent study carried out by the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK, has shown that Allogran-N can be used in combination with allograft for revision hip surgery. It concludes that Allogran-N can be a viable alternative to allograft in the event of shortage and help decrease the incidence of allograft transmitted infections by halving the number of bone donors in any one revision case.

A landmark in Sports Medicine
Posted in March 2009
Biocomposites has recently presented an award to Prof. James B Richardson (Robert Jones and Agnes Hunt Orthopaedic and District Hospital, Oswestry, UK), in recognition of hisinvaluable contribution to the development of the Bilok® interference screw, the world’s first globally marketed calcium composite implant for use in orthopaedic surgery.

Biocomposites Granted SFDA Clearance for geneX® in P.R.China
Posted in February 2009
Biocomposites (www.biocomposites.com) announced today that the company’s unique bone graft substitute geneX®, has been cleared for use by the State Food and Drug Administration (SFDA) of the People's Republic of China.

geneX® is a synthetic bone graft material with a unique bi-phasic composition manufactured through a proprietary process that confers the product with a reproducible negative surface charge. This property stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis. geneX® is fully resorbable and is completely replaced by bone.

Biocomposites Releases geneX® putty
Posted in July 2008
Biocomposites announced that the company’s unique bone graft substitute, geneX putty, has received FDA 510(k) clearance.
geneX is a resorbable bone graft material manufactured through a proprietary process that confers the product with a reproducible negative surface charge.
This property stimulates bone cell activity, accelerating bone formation by harnessing key proteins and directing osteoblast adhesion and proliferation for rapid osteogenesis.

Nicola Races Back to Health
Posted in July 2006
At 21 years old, Nicola Bauer was a promising undergraduate at Portsmouth University when a road traffic accident brought her education to an abrupt halt. The accident, in January 2000, resulted in multiple fractures including a grade II compound fracture of the left femur.
The Birmingham Post, Article - Healthy Diagnosis
Posted in January 2006
Some of the world’s leading footballers have North Staffordshire to thank for an often speedy recovery, yet few will actually realise that the cure to their injury has its roots in ceramics.
Biocomposites' Collaboration wins Nightingale Prize
Posted in November 2005
A collaboration between the research team at Biocomposites, and Keele University Institute of Science and Technology in Medicine (ISTM), has won the 2005 Nightingale Prize for the best scientific paper, awarded by the Institute of Physics and Engineering in Medicine (IPEM).
Interview with Stephen Bratt, Managing Director, Biocomposites
Published in Orthopaedic Product News, UK Edition, August 2005
Biocomposites may seem a relative newcomer to the orthopaedics industry. For five years, however, this specialist company in calcium composite technologies has led the way in the evolution of absorbable bioactive materials. BiLok® and Biosteon® devices represented the first calcium/polymer composite products in orthopaedics, cleared for patient use in arthroscopy in the late 1990’s. Biocomposites’ history stretches back to the early 19th century, giving the company an unrivalled pedigree in calcium salts processing.
Governor of the Bank of England visits Biocomposites' State of the Art Facilities
Posted in March 2005
The Governor of the Bank of England, Mr. Mervyn King, visited Biocomposites on a recent visit to the UK regions. Mr. King received a tour of the biomedical company's new custom built clean room, manufacturing and sales and marketing facilities at Keele, Staffordshire.
 
>> TOP OF PAGE
All content on this website is © Biocomposites Ltd., unless otherwise stated. All rights reserved. Disclaimer and Privacy Policy.